Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
435.62
+3.62 (0.84%)
At close: Mar 2, 2026, 4:00 PM EST
430.00
-5.62 (-1.29%)
Pre-market: Mar 3, 2026, 7:19 AM EST
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts that cover Madrigal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $637.92, which forecasts a 46.44% increase in the stock price over the next year. The lowest target is $405 and the highest is $964.
Price Target: $637.92 (+46.44%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 9 | 8 | 8 |
| Buy | 2 | 3 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 13 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $570 → $529 | Hold | Maintains | $570 → $529 | +21.44% | Feb 20, 2026 |
| Barclays | Barclays | Buy Initiates $964 | Buy | Initiates | $964 | +121.29% | Jan 28, 2026 |
| Citizens | Citizens | Buy Maintains $527 → $745 | Buy | Maintains | $527 → $745 | +71.02% | Jan 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $540 → $900 | Buy | Maintains | $540 → $900 | +106.60% | Dec 19, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $560 → $670 | Strong Buy | Maintains | $560 → $670 | +53.80% | Dec 11, 2025 |
Financial Forecast
Revenue This Year
1.48B
from 958.40M
Increased by 54.74%
Revenue Next Year
2.16B
from 1.48B
Increased by 45.72%
EPS This Year
1.05
from -12.85
EPS Next Year
17.85
from 1.05
Increased by 1,596.75%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.7B | 2.8B | |||
| Avg | 1.5B | 2.2B | |||
| Low | 1.2B | 1.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 74.6% | 87.7% | |||
| Avg | 54.7% | 45.7% | |||
| Low | 25.4% | 11.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 9.35 | 40.53 | |||
| Avg | 1.05 | 17.85 | |||
| Low | -6.84 | 4.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 3,752.5% | |||
| Avg | - | 1,596.7% | |||
| Low | - | 290.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.